SRR8613773
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.610
- UV_RESPONSE_DN+0.480
- IL6_JAK_STAT3_SIGNALING+0.440
- ALLOGRAFT_REJECTION+0.430
- INFLAMMATORY_RESPONSE+0.410
- COMPLEMENT+0.370
- IL2_STAT5_SIGNALING+0.360
- KRAS_SIGNALING_UP+0.320
- PANCREAS_BETA_CELLS+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- GLYCOLYSIS-0.400
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.370
- MTORC1_SIGNALING-0.350
- E2F_TARGETS-0.340
- DNA_REPAIR-0.320
- CHOLESTEROL_HOMEOSTASIS-0.310
- G2M_CHECKPOINT-0.310
- ESTROGEN_RESPONSE_LATE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613789 | — | A | 0.936 |
| 2 | 20030005.Her2HRpos | — | A | 0.930 |
| 3 | TCGA-55-6971-01A-11R-1949-07 | — | cohortMD2 | 0.914 |
| 4 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.907 |
| 5 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.894 |
| 6 | SRR8518454 | — | D | 0.886 |
| 7 | DRR168577 | — | — | 0.885 |
| 8 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.881 |
| 9 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.878 |
| 10 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |